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Objective: It is unclear, if the association between abnormalities in glucose metabolism (dysglycemia) and
impaired cognitive functioning is primarily driven by degenerative or vascular brain damage. We therefore
examined the relation between dysglycemia and brain volume and vascular lesions on MRI in a memory
clinic population.
Methods: The relations between markers of glycemia (HbA1c and fasting glucose levels) and normalized
brain volume, medial temporal lobe atrophy and vascular lesions (white matter hyperintensities, lacunes)
were assessed in 274 consecutive patients attending a memory clinic, using linear regression analyses.
Results: Clinical diagnoses were subjective complaints (n=117), mild cognitive impairment (n=62),
Alzheimer's disease (n=61) and other type of dementia (n=34). Twenty patients had a history of diabetes.
Across the whole study population there was no relation between HbA1c or fasting glucose and the brain MRI
measurements, after adjustments for age, sex and diagnostic group. Secondary analyses after stratiﬁcation by
diabetes status, diagnosis and median age (67 years) did not change the results.
Conclusion: In this memory clinic population, dysglycemia was not associated with either brain volume or
vascular lesions. Apparently, dysglycemia is not associated with a speciﬁc class of brain pathology in patients
with cognitive complaints.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Diabetes mellitus type 2 (DM2) [Reviews: [Cukierman, Gerstein, &
Williamson, 2005; Kloppenborg, van den Berg, Kappelle, & Biessels,
2008]], as well as disturbances in glucose metabolism that do not yet
meet the criteria for diabetes [Gao, Matthews, Sargeant, & Brayne,
2008], is associated with impaired cognitive performance and an
increased risk of dementia. Adults with DM2 have approximately a
two-fold greater risk of dementia compared to adults without DM2
[Biessels, Staekenborg, Brunner, Brayne, & Scheltens, 2006]. At present
it is unclear if this increased risk reﬂects a causal relationship between
diabetes-related metabolic and vascular disturbances and dementia.
Theoretically, the increased dementia risk might be due to elevatedﬂict of interest to declare.
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l rights reserved.glucose levels, or to factors that occur in associationwith disturbances
in glucose metabolism, such as hypertension, dyslipidemia or obesity.
Moreover, it is uncertain if the relation between disturbances in
glucose metabolism (dysglycemia) and dementia is primarily
reﬂected in neurodegenerative changes, vascular pathology, or both.
A recent autopsy study indicated that insulin resistance is associated
with Alzheimer type pathology [Matsuzaki et al., 2010]. However,
other studies indicate that people with DM2 have less Alzheimer
pathology but increased vascular pathology in their brain, even if their
clinical diagnosis in life was Alzheimer's disease (AD) [Arvanitakis
et al., 2006; Ronnemaa et al., 2009].
Brain imaging studies might help to clarify the nature of the
relation between dysglycemia and impaired cognition. The relation
between dysglycemia and brain magnetic resonance imaging (MRI)
abnormalities has been assessed in population based studies, but
never in a cohort of patients with memory complaints. We therefore
examined levels of glycated hemoglobin (HbA1c) and fasting glucose
in relation to neurodegenerative changes and vascular lesions on MRI
in patients attending a memory clinic. In this study population, early
features of dementia and associated brain imaging abnormalities are
more pronounced compared to a population based setting. Moreover,
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such patients, hence allowing us to determinewhether dysglycemia is
associated with a speciﬁc class of MRI abnormalities in people with
cognitive complaints.
2. Method
2.1. Study population
Patients were recruited from the outpatient memory clinic of the
Alzheimer centre of the VUUniversityMedical Centre (VUmc). Patients
received a standardised diagnostic assessment including an interview
on medical history, medication use and education level, a physical
examination, neurological examination, neuropsychological testing,
including the mini mental state examination (MMSE), an MRI-scan of
the brain and blood tests. Patients were requested to bring a relative or
good friend, to decreases the chance of incomplete health status
information. In each patient the clinical diagnosis was made at a
multidisciplinary consensus meeting based on internationally estab-
lished diagnostic criteria. Patients with the following four diagnoses
were eligible for this study: 1) Possible or probable AD [McKhann,
Drachman, Folstein, Katzman, Price, & Stadlan, 1984], 2) Mild cognitive
impairment [Petersen et al., 2001], 3) subjective complaints without
cognitive impairment on neuropsychological assessment (subjective
cognitive impairment) and 4) other dementia (including subjects with
frontotemporal lobar degeneration, vascular dementia, Dementia with
Lewy Bodies). Diabetes diagnosis was based on self-reported history.
The present study includes all consecutive patients that visited the
clinic in the preceding 3 years, from whom HbA1c levels and a MRI at
the time of diagnoses were available, who met the four diagnostic
groups outlined above, and who had an MMSE score above 22.
Patients younger than 45 years or with other pre-existent neurolog-
ical or psychiatric disorders were excluded. This resulted in a study
population of 274 patients.
2.2. Laboratory variables
Fasting glucose and HbA1c were determined in EDTA plasma at
the Department of Clinical Chemistry of the VUmc. For the statistical
analyses HbA1c and fasting glucose were categorized in quartiles.
2.3. MRI
2.3.1. MRI acquisition
MR imaging was performed on a 1.0-T Siemens Magnetom Impact
Expert scanner (Siemens AG, Erlangen, Germany) and included
coronal T1-weighted 3D MPRAGE volumes (magnetization prepared
rapid acquisition gradient echo; single slab 168 slices; matrix
256×256; FOV 250 mm; voxel size 1 mm×1 mm×1.5 mm; repeti-
tion time=15 ms; echo time=7 ms; inversion time=300 ms; ﬂip
angle 15) and a fast ﬂuid attenuated inversion recovery (FLAIR)
sequence (axial, 5-mm contiguous slice, 1-mm in-plane resolution).
Scans were reviewed by a radiologist to exclude non-neurodegener-
ative pathology that could explain the cognitive impairment.
2.3.2. Brain volume
Whole-brain volume was measured with an adaptation of
Structural Image Evaluation, using Normalisation, of Atrophy
(SIENA) called SIENAX, a fully automated technique part of FSL (for
a detailed explanation see: http://www.fmrib.ox.ac.uk/analysis/re-
search/siena/) [Smith et al., 2002]. SIENAX is closely related to the
SIENA longitudinal method, but, instead of using images from two
different time points, SIENAX attempts to estimate normalized brain
volume (NBV) using a single time point. Brieﬂy, the brain and skull
were extracted using the brain extraction tool [Smith et al., 2004].Compared to standard SIENAX, the procedure to remove non-brain
tissue was slightly modiﬁed, because the brain extraction tool (BET)
may leave signiﬁcant amounts of non-brain tissue (e.g. skull,
meninges), while also removing cortex in some areas [Hartley,
Scher, Korf, White, & Launer, 2006]. To remove all non-brain tissue
without losing cortex, we incorporated in the procedure the
registration of a template mask to the individual scans [Sluimer
et al., 2008]. After this modiﬁed brain extraction procedure, the
standard SIENAXpipelinewas continued. The brain is registered to the
standard brain, using the skull as the scaling constraint, supplying a
normalisation transform. The tissue segmentation program segments
the extracted brain image into grey,white, CSF and background, giving
a brain volume (BV) estimate. This is multiplied by a volumetric
scaling factor (derived from the normalisation transform), to give
normalized brain volume in cm3 (NBV). All individual scans,
registration results, and SIENAX output were reviewed by a rater
who was blinded to the diagnosis. The SIENAX method is highly
reproducible and was reported to have an absolute median difference
of 0.96% between two analyses of the same scan [Cover et al., 2011].
Twenty-ﬁve scans were excluded in the SIENAX process because of an
inappropriate result or inadequate quality of the scan. These 25
patients were evenly distributed across all diagnostic groups.The
method used to calculate hippocampal volume was described in
detail elsewhere [Henneman et al., 2009a]. In short, hippocampi on
both sides were manually delineated using the software package
“Show_Images 3.7.0” (in-house developed at VU University Medical
Center, 2003), by three trained technicians (coefﬁcients of variation
reproducibility: interrater b8%, intrarater b5%). Volumes of the right
and left site were averaged and adjusted for intracranial volume,
using the scaling factor derived from SIENAX (see above).
2.3.3. Visual rating
Medial temporal lobe atrophy (MTA) was evaluated using a visual
rating scale [Scheltens et al., 1992] on coronal T1-weighted images
based on the choroid ﬁssure width, the temporal horn width, and the
hippocampal height (possible range of scores for each side, 0 to 4).
Scores of the right and left site were averaged. The degree of WMH
severity was rated visually on axial FLAIR images using the modiﬁed
Fazekas scale (WMH grade, none, mild, moderate, severe, 0 to 3)
[Fazekas, Chawluk, Alavi, Hurtig, & Zimmerman, 1987]. Lacunes were
deﬁned as T1-hypointense and T2-hyperintense CSF-like lesions that
were surrounded by white matter or subcortical gray matter and not
located in areaswith a high prevalence ofwidened perivascular spaces
(e.g., anterior commissure region) [van Straaten et al., 2003]. Ratings
were performed blinded to clinical information, with the use of digital
image ﬁles. Raters were trained and had an accuracy against an
internally established gold standard with weighted Cohen k scores
N0.80 both forMTA andWMH [Henneman et al., 2009b] and all ratings
were veriﬁed by a second observer. There was 1 missing WMH score
and 5 missing lacune ratings.
2.4. Statistics
Statistical analyses were performed using SPSS 17.0 for Windows.
The associations between quartiles of HbA1c and fasting glucose
levels (independent variables in separate models) and NBV (depen-
dent variable) were assessed with linear regression analysis across
the whole study population. Because of non-normal distribution NBV
was log-transformed for these analyses. The analyses were adjusted
for age, sex and diagnostic group (using dummy variables). Data are
presented as standardized beta coefﬁcient with accompanying 95%
conﬁdence interval.
The imaging variables that were based on visual rating were
dichotomized for logistic regression analyses: WMH absent (score 0–
1) or present (2–3), lacunes absent (0) or present (number ≥1), left/
Table 1
Population characteristics.
All N=274 SC N=117 MCI N=62 AD N=61 Dementia other n=34
Age, years 67±9 61±8 69±7 73±7 69±9
Sex, male 158 (58%) 56 (48%) 44 (71%) 32 (52%) 26 (77%)
MMSE 27±2 29±1 28±2 25±2 27±2
Reported DM 20 (7%) 5 (4%) 7 (11%) 5 (8%) 3 (9%)
HbA1c, % 5.8±0.6 5.7±0.6 5.7±0.5 5.9±0.8 5.7±0.4
Fasting glucose, mmol/l; n=261 5.4±1.3 5.3±1.2 5.2±1.0 5.6±1.8 5.4±1.3
NBV, ml; n=251 1,514±117 1,558±110 1,503±102 1,460±111 1,478±118
MTA, scale 0–4; n=274 0.5 (0–1.5) 0 (0–0.5) 0.5 (0–1.5) 1.5 (0.5-2) 1.0 (0–2.0)
WMH, scale 0–3; n=273 1.0 (0–1.0) 0 (0–1.0) 1.0 (0–1.0) 1.0 (0–2.0) 1.0 (0–1.0)
Presence of ≥1 lacune; n=269 48 (18%) 17 (15%) 12 (20%) 9 (15%) 10 (32%)
Mean scores±standard deviation or n (%), and for MTA and WMH median scores with (IQR).
MMSE=mini-mental state examination, DM=Diabetes Mellitus, NBV=Normalized Brain Volume, MTA=Medial Temporal lobe Atrophy, WMH=White Matter Hyperintensity,
SC=Subjective Complaints MCI=Mild Cognitive Impairment, AD=Alzheimer's Disease, Dementia other=other type of dementia than Alzheimer's disease.
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between quartiles of HbA1c and fasting glucose levels (independent
variables in separate models) and MTA, WMH and lacunes (depen-
dent variables) were assessed with logistic regression analysis across
the whole study population. The analyses were adjusted for age, sex
and diagnostic group (using dummy variables).
All analyses were repeated after stratiﬁcation for DM and for
diagnosis. Finally, to investigate a possible modulating effect of age,
we performed separate analyses for those above and below the
median age. The level of statistical signiﬁcance was set at pb0.05.100,0%
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Fig. 1.Distribution of MTA (0–4) orWMH (0–3) scores per quartile of HbA1c or glucose. The
bars represent WMH, white is no WMH (0) and the darker the higher WMH score. The strip
MTA=medial temporal lobe atrophy. WMH=white matter hyperintensity.3. Results
Demographic and clinical data are presented in Table 1. Mean age
was 67 years (SD 9), 58% of the participants was male. The clinical
diagnosis was subjective complaints in 117 patients, MCI in 62, AD in
61, and other type of dementia in 34 (17 with FTLD, 5 with VaD and 7
with DLB, 5 other types). As would be expected, MMSE scores and
NBV were lower, and MTA and WMH ratings higher in the patients
with AD (pb0.001), compared to the other diagnostic groups. There
were no differences in HbA1c levels, fasting glucose levels and the100,0%
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MTA score is an average score of left and right, rounded to the closest integer. The dotted
ed bars represent MTA, white is no MTA (0) and the darker the higher the MTA score.
Table 2
Relation between HbA1c, brain volume and vascular lesions.
Quartiles HbA1c Regression analyses (n=274)
≤5.4% 5.5%–5.6% 5.7%–5.8% ≥5.9% Unadjusted Adjusteda
Mean±SD Beta (95% CI)
NBV (ml) 1527±118 1501±114 1528±123 1505±114 − .04 (− .17 .09) .09 (− .03 .20)
No. (%) OR (95% CI)
MTA 15 (19%) 23 (32%) 13 (28%) 25 (33%) 1.2 (0.97 1.5) 1.0 (0.8 1.4)
WMH 6 (8%) 17 (23%) 10 (21%) 10 (13%) 1.1 (0.8 1.5) 0.9 (0.7 1.3)
Lacunes 13 (17%) 12 (17%) 8 (17%) 15 (20%) 1.1 (0.8 1.4) 1.0 (0.7 1.3)
Mean normalized brain volume (NBV) and proportions of individuals with medial temporal lobe atrophy (MTA), white matter hyperintensities (WMHs), or lacunes are presented
per quartile of HbA1c.
The relation between HbA1c and brain MRI abnormalities was assessed with linear (log transformed NBV) or logistic regression analysis (MTA, WHM and lacunes) across
the quartiles.
a Analyses adjusted for age, sex and diagnostic group. Beta: standardized regression coefﬁcient; OR: Odds ratio.
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clinical diagnosis of diabetes of which 19 used glucose-lowering
medication. Three patients used antipsychotic medication of which
one has diabetes.
The distributions of WMH and MTA grading per quartiles of either
HbA1c or glucose are presented in Fig. 1. The quartiles of HbA1c did
not show a speciﬁc pattern of WMH or MTA grading and the
proportion of patients with severeMTA orWMHwas not higher in the
upper or lower quartile of HbA1c. The results were the same for
fasting glucose. Regression analyses showed no signiﬁcant relation
between either HbA1c (Table 2) or fasting glucose (Table 3) and any
of the brain MRI measures. Repeated analyses after exclusion of
patients with a known history of diabetes showed similar results.
In secondary analyses the associations between HbA1 and fasting
glucose and the brain MRI markers were repeated after stratiﬁcation
by diagnostic group. The results remained essentially the same. In the
AD group, for example, standardized regression coefﬁcients per
quartile of HbA1c were 0.05 (95% CI: − .25 .35) with normalized
brain volume. Odds ratios (ORs) per quartile increase in HbA1c were
1.0 (95% CI 0.6 1.9) for MTA, 0.6 (0.3 1.1) for WMH, and 0.7 (0.3 1.3)
for lacunes (data for the other diagnostic groups not shown).
We also separated the sample in older and younger patients based
on the median age of 67 years, and observed that the relations
between glucose, HbA1c and the MRI measures were similar in both
age groups. In the younger than 67 years age group, standardized
regression coefﬁcients per quartile of HbA1c were 0.03 (95% CI:− .12
.18) with normalized brain volume. ORs per quartile increase in
HbA1c were 0.9 (95% CI 0.6 1.5) for MTA, 1.0 (0.7 1.4) for WMH, and
1.2 (0.8 1.9) for lacunes. In the 67 years and older group, standardized
regression coefﬁcients per quartile of HbA1c were 0.05 (95% CI:− .14
.23) with normalized brain volume. ORs per quartile increase in
HbA1c were 0.9 (95% CI 0.6 1.3) for MTA, 1.0 (0.7 1.4) for WMH, and
0.8 (0.5 1.1) for lacunes.
Normalized hippocampal volumes were known for 177 (64%) of
the subjects. This sub-set of patients had a similar average age (67 ±Table 3
Relation between glucose, brain atrophy and vascular lesions.
Quartiles Glucose
≤4.6 mmol/l 4.7–5.0 mmol/l 5.1–5.7 mmo
Mean±SD
NBV (ml) 1517±129 1526±131 1507±100
No. (%)
MTA 16 (25%) 16 (25%) 21 (29%)
WMH 6 (10%) 13 (21%) 14 (19%)
Lacunes 8 (13%) 9 (15%) 13 (18%)
Mean normalized Brain Volume (NBV) and proportions of individuals with medial tempora
per quartile of glucose.
The relation between HbA1c and brain MRI abnormalities was assessed with linear (log
the quartiles.
a Analyses adjusted for age, sex and diagnostic group. Beta: standardized regression9 years) and MMSE score (27±2), a similar distribution of gender
(57%), DM cases (7%) and clinical diagnosis (40% SC; 29%MCI; 23% AD
and 8% dementia other) as the total cohort. To complement the MTA
results, we analyzed normalized hippocampal volume in linear
regression analyses (similar to NBV adjusted for age, sex and
diagnostic group) and found no signiﬁcant relation between HbA1c
(standardized Beta .06; 95% conﬁdence interval (CI) − .07 .20) or
fasting glucose (standardized Beta − .02; 95% CI − .16 .11) and
normalized hippocampal volume.
4. Discussion
HbA1c or fasting glucose levels were unrelated to atrophy or
vascular lesions on brain MRI in this memory clinic population.
Apparently, dysglycemia is not associated with a speciﬁc class of brain
lesions in these patients.
The relation between dysglycemia and brain MRI abnormalities
has been assessed in population and clinic based studies, but never
speciﬁcally in a cohort of persons with memory complaints. None of
the previous studies presented both vascular brain abnormalities and
brain atrophy and most of these studies did not primarily concern the
relation between dysglycemia and brain MRI abnormalities. In non-
demented community-dwelling elderly subjects, WMHs are associ-
ated with elevated levels of HbA1c [Murray, Staff, Shenkin, Deary,
Starr, &Whalley, 2005]. In a Europeanmulticenter (LADIS) study [Gao
et al., 2008], elevated fasting blood glucose level was identiﬁed as a
risk factor for WMH progression, but not for new lacunes. A study
[Convit, Wolf, Tarshish, & de Leon, 2003] in normal nondiabetic
middle-aged and elderly individuals, found that those with poorer
peripheral glucose regulation were more likely to have smaller head
size-adjusted hippocampal volumes. No associations were found for
the volumes of other brain regions, including a measure of overall
brain atrophy. A longitudinal study [Enzinger et al., 2005], identiﬁed
elevated HbA1c as a risk factor for a greater rate of brain atrophy.
Apparently, dysglycemia is associated with both vascular brainRegression analyses (n=261)
l/l ≥5.8 mmol/l Unadjusted Adjusteda
Beta (95% CI)
1515±109 − .02 (− .14 .11) .09 (− .02 .21)
OR (95% CI)
19 (31%) 1.1 (0.9 1.4) 0.96 (0.7 1.3)
9 (15%) 1.1 (0.8 1.5) 0.97 (0.7 1.3)
15 (25%) 1.3 (0.98 1.8) 1.2 (0.9 1.7)
l lobe atrophy (MTA), white matter hyperintensities (WMHs), or lacunes are presented
transformed NBV) or logistic regression analysis (MTA, WHM and lacunes) across
coefﬁcient; OR: Odds ratio.
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population, although not all studies observe this association.
Previous imaging studies in patients with DM2 [van Harten, de
Leeuw, Weinstein, Scheltens, & Biessels, 2006] have shown that both
vascular brain abnormalities (such as lacunes,WMH) and neurodegen-
erative changes (such as cortical, subcortical and hippocampal atrophy)
on brain MRI are relatively more pronounced than in non-diabetic
controls. It is unclear, however, if these DM2-associated brain MRI
abnormalities are causally linked to elevated glucose levels, or to other
diabetes associated factors. There are eight studies in ﬁve non-
demented cohorts (with DM2 and control patients) on the brain MRI
abnormalities in DM2 that provide secondary analyses on the relation
betweenmarkers of glycemia [24–31]. Generally, these studies foundno
association between dysglycemia and vascular abnormalities in DM2
patients [van Elderen et al., 2010; Jongen, van der Grond, Kappelle,
Biessels, Viergever, & Pluim, 2007; Manschot et al., 2006] [but see
[Tiehuis et al., 2008; vanHarten, Oosterman, Potter van Loon, Scheltens,
& Weinstein, 2007]]. Two studies that looked at hippocampus atrophy
in DM2 patients [Gold et al., 2007; Sakurai et al., 2006] found an
association with dysglycemia. The evidence for an association between
dysglycemia andmore general brain atrophymeasures in DM2 patients
is also inconsistent [de Bresser et al., 2010; Jongenet al., 2007;Manschot
et al., 2006; Tiehuis et al., 2008; van Elderen et al., 2010; van Harten
et al., 2007].
In the current study, HbA1c and fasting glucose levels were
unrelated to atrophy or vascular lesions on brain MRI in subjects with
memory complaints. Apparently, dysglycemia is not associated with a
speciﬁc class of brain lesions in these patients. This is in line with
previous studies on the relation between dysglycemia and brain
volumes on MRI among patients with DM2, but in apparent contrast
with the majority of studies on the relation between dysglycemia and
brain volumes in the general population. There are several possible
explanations for these ﬁndings. The main difference with previous
studies on this topic is that we studied subjects presenting at a
memory clinic. A factor that predisposes to dementia at the
population level does not necessarily have to be associated with
more severe symptoms or brain MRI abnormalities at the time of
presentation in a memory clinic setting. Nevertheless, the strength of
studies in memory clinic populations is that it can help to identify
speciﬁc cognitive or brain MRI phenotypes of presumed etiological
factors for cognitive decline and dementia, in a population in which
early features of dementia are common. In population based studies of
older individuals the situation is quite different. In this setting,
increased atrophy and vascular lesions are a marker of processes that
can ultimately lead to dementia. Hence the observed associations
between HbA1c and brain MRI abnormalities in population based
studies [Convit et al., 2003; Enzinger et al., 2005; Gouw et al., 2008;
Murray et al., 2005] are in line with the observed association between
HbA1c and elevated dementia risk [Gouw et al., 2008]. Nevertheless,
these observations cannot be taken as proof of an etiological role of
dysglycemia in dementia risk. Dysglycemia is related to insulin
resistance, which is strongly related to other vascular risk factors. As
such, in the general population, elevated HbA1c levels might be a
proxy for elevated vascular risk, which may not always be sufﬁciently
accounted for in multivariate analyses in previous studies.
Strengths of our study are the large number of subjects with both
normal and abnormal brain MRI ﬁndings, and the standardized
diagnostic evaluation. Some limitations should also be considered. As
indicated above, observations in a memory clinic population might
not be generalizable to the population at large. Importantly, our
negative ﬁndings are not likely to be due to limited statistical power.
The point estimates for the standardized regression coefﬁcients were
close to zero (or 1 for the odds ratios), with relatively narrow 95%
conﬁdence intervals, indicating that variation in HbA1c could explain
atmost a few percent of the variation (coefﬁcient of determination) inthe brain volumes. Our patients were relatively young, 5–10 years
younger than a usual dementia sample, which could also affect the
results. However, age did not seem to modify the relation between
dysglycemia and the brain MRI measurement in the stratiﬁed
analyses. With regard to the markers of dysglycemia; HbA1c and
fasting glucose levels were the only measures available, and showed
relatively low variance in our population. It could be that studies on
populations with highly elevated HbA1c and fasting glucose levels or
studies using other measures of glucose or insulin metabolism, in the
blood or in the brain, would provide other results. Although all the
applied MRI measures are well-established, the Fazekas score is a
rather crude method to classify WMH, which could potentially mask
small effect sizes. Volumetric measurements are obviously more
sensitive. Finally, our study has a cross-sectional design. We can
therefore not determine if dysglycemia is associated with accelerated
brain atrophy or vascular lesion progression. The inﬂuence of
heterogeneity between subjects is decreased in a longitudinal study,
since the change over time can be studied without the effect of
already accumulated brain lesions.
In conclusion, the present study shows that among people visiting
a memory clinic for cognitive complaints dysglycemia is not
associated with a speciﬁc class of brain abnormalities at MRI. This
seems to be in contrast to population based studies, where both
vascular brain abnormalities and neurodegenerative changes have
been associated with dysglycemia. All in all, there is inconsistent
evidence to clarify which pathological processes – Alzheimer type
pathology or vascular pathology – drive the association between
dysglycemia and impaired cognition. Further research, preferably
with volumetric measures, is needed to unravel the possible role of
dysglycemia in the aetiology of cognitive impairment.
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